Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
23,796 total articles
BridgeBio Pharma announced they will present new late-breaking and longer-term data on oral infigratinib, a drug targeting achondroplasia, at the Annual European Society for Paediatric Endocrinology Meeting 2026. The data include results from the PROPEL 3 randomized controlled trial, longer-term safety and efficacy findings, and ongoing studies in …
OptimizeRx Corp. has appointed Troy Sarich, an expert in pharmaceutical commercialization and artificial intelligence, as a company advisor. Sarich's extensive experience at Johnson & Johnson and deep expertise in data analytics will help OptimizeRx enhance its healthcare technology solutions, facilitating better engagement between life sciences br…
Zevra Therapeutics, a commercial-stage biopharmaceutical company focused on rare diseases, announced that its executive leadership will present at three major healthcare investor conferences in New York in September 2026. These presentations aim to update investors on the company's progress and strategic direction. Zevra's lead product targets Niem…
Cronos Group Inc. announced an expansion of its Spinach® brand product line, introducing new edible multipacks featuring their first live resin gummy and new vape cartridge flavors. These additions build on Spinach®'s position as Canada's leading edible and vape brand, with planned broader national availability.
Algoma Steel Group Inc. reports progress on managing the unplanned outage at its Lake Superior Power generating facility. Through interim measures coordinated with Ontario's electricity operator, the company has resumed electric arc furnace production and is pursuing options to repair or replace the affected turbine. Algoma continues to evaluate pr…
FuelCell Energy reported Q3 FY2026 results highlighting a substantial increase in its backlog to $3.6 billion driven by new agreements including a major data center power supply contract. The company is progressing its manufacturing facility expansion to target 500 MW annualized capacity by 2028 and aims for positive Adjusted EBITDA by Q4 FY2027. S…
Quantum Cyber N.V., a Nasdaq-listed autonomous defense technology company, has appointed Tzvi Lev as Head of Sales for the Middle East to spearhead commercial expansion across the Gulf Cooperation Council and Israel. Leveraging Lev's extensive defense, diplomatic, and regional market experience, the company aims to convert its advanced autonomous d…
Daktronics, Inc., a leader in digital display technologies, announced fiscal 2027 first quarter results with a 21.2% increase in diluted EPS to $0.40 on 7.1% sales growth, achieving a 10.6% operating margin. The company maintained a product backlog exceeding $300 million for the sixth straight quarter and ended the quarter with a strong cash positi…
Edible Garden AG Incorporated has officially regained compliance with Nasdaq’s minimum bid price rule, enabling it to maintain its listing and focus on executing growth strategies including expanding its Webster City facility to manufacture ready-to-drink nutrition products and advancing its Farm-to-Formula® platform.
uniQure has submitted a Biologics License Application (BLA) to the U.S. FDA and a Marketing Authorisation Application (MAA) to the U.K.'s MHRA for its investigational gene therapy ifezuntirgene inilparvovec (AMT-130) for Huntington's disease. The applications are based on three-year Phase I/II study data showing slowed disease progression and the c…
Lifecore Biomedical has signed a significant agreement to perform tech transfer and commercial manufacturing for a commercially marketed injectable drug product from a global pharmaceutical company. This program, expected to generate revenue starting in 2028, further strengthens Lifecore's late-stage commercial pipeline and expands its customer bas…
Teva Pharmaceutical Industries announced positive topline Phase 2a study results for TEV-408, an investigational anti-IL-15 antibody. The drug showed statistically significant and clinically meaningful prevention of gluten-induced intestinal damage in celiac disease patients, with a favorable safety profile. TEV-408 also demonstrated a reduction in…
Lexeo Therapeutics, a clinical-stage genetic medicine company focused on cardiovascular disease treatments, announced its management team's participation in two investor conferences in September 2026. These engagements aim to update investors on the company's progress and pipeline developments, including novel therapies targeting genetic causes of …
Rapport Therapeutics, a clinical-stage biotech company focused on precision small molecule medicines for neurological and psychiatric disorders, will participate in upcoming investor events including the Cantor Global Healthcare Conference and TD Cowen Neuropsychiatry Summit. Management will discuss its RAP technology platform and lead drug candida…
MediWound Ltd., a biotech company specializing in enzymatic, non-surgical therapies for tissue repair, announced that CEO Ofer Gonen will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York City. The event includes a fireside chat moderated by a senior healthcare analyst, providing a platform to discuss company devel…
Wrap Technologies announced the development of a new law enforcement doctrine and training curriculum designed to operationalize de-escalation utilizing its BolaWrap 150 device, recently classified by the ATF as an instrument of restraint rather than a firearm. The company has submitted the curriculum for independent validation and California Peace…
Can-Fite BioPharma reports that overall survival in its ongoing pivotal Phase III trial of Namodenoson for advanced hepatocellular carcinoma (HCC) is longer than initially expected, prompting plans to advance the interim analysis. While the trial remains blinded, this positive signal may indicate potential clinical benefit for patients with substan…
Aeluma, a NASDAQ-listed semiconductor company specializing in scalable photonic and electronic technologies, announced it will release its fourth quarter and fiscal year 2026 financial results after market close on September 16, 2026. The company will host an investor conference call the same day to discuss its financial performance and business ou…
Tonix Pharmaceuticals announced participation in Cantor's 2026 Global Healthcare Conference featuring a fireside chat with CEO Dr. Seth Lederman. The company showcased its focus on CNS disorders, infectious diseases, immunology, and rare diseases with marketed products including TONMYA® for fibromyalgia and migraine treatments, along with advancing…
Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on novel therapeutics targeting metabolic and fibrotic pathways, announced its management participation at the Cantor 2026 Global Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference in New York. The events include a fireside chat to be held an…
CoinShares PLC has completed the acquisition of Bastion Asset Management, integrating Bastion's systematic investment team and strategies into its Active Alternative Strategies business. The acquisition enhances CoinShares' ability to offer both passive and active digital asset investment strategies, broadening its institutional platform and produc…
VEON Ltd. will release its consolidated financial and operating results for Q3 2026 on November 6, 2026, followed by a conference call with senior management. Additionally, the company will hold a Capital Markets Day on November 16, 2026, to discuss strategic priorities, business performance, and long-term value creation.
FactSet will release its financial results for the fourth quarter of fiscal 2026 on September 30, 2026, followed by a conference call to discuss the results. The earnings presentation and a replay will be accessible on the company's Investor Relations website.
Opus Genetics announced it will present topline data from Cohort 1 of its Phase 1/2 study of OPGx-BEST1 gene therapy targeting BEST1-related inherited retinal diseases. The data presentation is scheduled for September 9, 2026, followed by full clinical datasets at major ophthalmology conferences. OPGx-BEST1 uses an AAV vector to deliver a functiona…
Fortrea has signed a definitive agreement to acquire the Early Phase Services division of Worldwide Clinical Trials, including a clinical pharmacology unit, bioanalytical laboratory, and biospecimen storage facilities in Texas. This acquisition strengthens Fortrea’s integrated clinical development platform from first-in-human studies through Phase …
